SCHEMBL4581732

SCHEMBL4581732

COCC[C@@]1(n2cnc3c(N)ncnc32)O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 5/20 0.49
ADORA2A P29274 3/20 0.49
GMPS P49915 1/20 0.49
PI4KA P42356 2/20 0.47
PI4K2B Q8TCG2 2/20 0.47
PI4K2A Q9BTU6 2/20 0.47
PI4KB Q9UBF8 2/20 0.47
SLC28A1 O00337 2/20 0.47
ADORA1 P30542 2/20 0.47
DPP4 P27487 1/20 0.47
MEN1 O00255 1/20 0.47
MAP3K7 O43318 1/20 0.47
SLC28A2 O43868 1/20 0.47
GAPDH P04406 1/20 0.47
MAPK1 P28482 1/20 0.47
ADORA2B P29275 1/20 0.47
STAT6 P42226 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
DOT1L Q8TEK3 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7207821 0.90 ADORA3 (0.48) ADORA3ADORA2AGMPSPI4KAPI4K2B
SCHEMBL2534138 0.89 ADORA3 (0.52) ADORA3ADORA2AGMPSPI4KAPI4K2B
SCHEMBL29639535 0.88 ADORA3 (0.54) ADORA3ADORA2AGMPSPI4KAPI4K2B
SCHEMBL2270714 0.88 ADORA3 (0.54) ADORA3ADORA2AGMPSPI4KAPI4K2B
SCHEMBL6828797 0.87 ADORA3 (0.53) ADORA3ADORA2AGMPSPI4KAPI4K2B
SCHEMBL3624014 0.87 ADORA2A (0.42) ADORA3ADORA2AADORA1ADORA2BAHCY
SCHEMBL9512681 0.87 FGFR1 (0.52) ADORA3ADORA2AGMPSPI4KAPI4K2B
SCHEMBL29509039 0.87 ADORA3 (0.50) ADORA3ADORA2AGMPSPI4KAPI4K2B
SCHEMBL10786319 0.86 ADORA3 (0.52) ADORA3ADORA2AGMPSPI4KAPI4K2B
SCHEMBL3698843 0.86 ADORA3 (0.54) ADORA3ADORA2AGMPSPI4KAPI4K2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114729363-A IL-34 antisense agents and methods of use thereof 诺格拉制药有限公司 2022-07-08 CN claimed
CN-118891366-A SiRNA inhibiting expression of transferrin receptor 2 第一三共株式会社 2024-11-01 CN disclosed
CN-118871585-A Chemically-modified oligonucleotides with RNAi activity 第一三共株式会社 2024-10-29 CN disclosed
CN-114729363-A IL-34 antisense agents and methods of use thereof 诺格拉制药有限公司 2022-07-08 CN disclosed
CN-114555069-A Oligonucleotides and methods for treating neurological diseases 奎里斯公司 2022-05-27 CN disclosed
US-7371852-B2 Alkyl-linked nucleotide compositions SERENEX, INC. (US) 2008-05-13 US disclosed
EP-1585754-A2 ALKYL-LINKED NUCLEOTIDE COMPOSITIONS Serenex, Inc. (US) 2005-10-19 EP disclosed
US-20040215009-A1 Alkyl-linked nucleotide compositions SERENEX, INC. (US) 2004-10-28 US disclosed
WO-2004065566-A2 ALKYL-LINKED NUCLEOTIDE COMPOSITIONS SERENEX, INC. (US) 2004-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040215009-A1 Alkyl-linked nucleotide compositions NT5C3B, NUDT1, NT5C2 ADORA3 124/4885ADORA2A 147/4885GMPS 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.